Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) delivered a quarter that reframes the investment case. Revenue hit a record, backlog exploded past $2 billion, and management inked a transformative deal to acquire Iridium.
Our 24/7 Wall St. price target for Rocket Lab is $120.55, implying meaningful upside from current levels. The recommendation is buy, with moderate confidence given execution risk on Neutron and multi-acquisition integration.
24/7 Wall St. Price Target Summary
| Metric | Value |
|---|---|
| Current Price | $80.04 |
| 24/7 Wall St. Price Target | $120.55 |
| Upside | 50.61% |
| Recommendation | BUY |
| Confidence Level | 50% |
A Record Quarter Meets a Volatile Tape
Rocket Lab shares are up 13.64% over the past week and 79.1% over the past year, but the stock still sits well below its 52-week high of $151.
Q2 FY2026, reported August 10, delivered revenue of $234.07 million, up 61.99% year over year and topping the $230.94 million consensus. GAAP EPS of -$0.08 missed expectations, weighed down by $8.58 million in acquisition transaction costs.
The signal is in the backlog: $2.36 billion, up 137% YoY, plus more than $1 billion in new contracts already signed in Q3. Q3 revenue guidance of $250 million to $265 million sets up another record.
The Case for $158 and Higher
Bulls have a clean story. The Iridium acquisition transforms Rocket Lab into a vertically integrated space communications platform. CEO Peter Beck framed it directly: “these moves position Rocket Lab to accelerate our future into space applications by becoming a self-launching, tier-1 space power that will deliver critical communications capability to millions of users worldwide.”
Layer in the $397 million U.S. Space Force Flatellite contract, first geostationary satellite production for the U.S. government, and a 90-plus launch backlog, and near-term revenue visibility is substantial.
Our bull-case target of $158.06, roughly a 97% return, is achievable if Neutron ships on time in Q4 2026 and Iridium closes cleanly.
What Could Go Wrong
The bear scenario centers on execution and dilution. Rocket Lab raised $1.53 billion via ATM in H1 2026, and Q3 weighted-share count is guided to 641 million shares.
CEO Beck sold heavily across July 6-8, 2026 at prices between $81.59 and $101.57, though the transactions appear consistent with systematic diversification at elevated valuations. Our bear-case target of $94.53 assumes Neutron slips and Iridium integration drags on GAAP losses through 2027.
How Rocket Lab Compares to AST SpaceMobile and Planet Labs
AST SpaceMobile (NASDAQ:ASTS) is the most relevant comp for the Iridium-era Rocket Lab thesis. ASTS carries a market cap of roughly $20.5 billion on Q2 revenue of just $31.5 million, a fraction of Rocket Lab’s top line. That contrast makes RKLB’s $46-52 billion market cap look expensive on absolute scale but reasonable on revenue-per-dollar-of-market-cap.
Planet Labs (NYSE:PL) is the small-satellite pure-play counterpoint. PL trades at a market cap of roughly $7.9 billion on FY2027 revenue guidance of $425 million to $441 million and adjusted EBITDA profitability. Planet generates positive cash flow, something Rocket Lab has yet to achieve.
On a price-to-sales basis, RKLB commands a steep premium (76x sales TTM) versus Planet’s more grounded multiple. Rocket Lab’s premium rests on launch monopoly economics and Iridium optionality rather than current fundamentals.
Rocket Lab Price Prediction 2026-2030
Here is where our model projects RKLB in the coming years, assuming Neutron enters commercial service and Iridium closes.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $120.55 |
| 2027 | $155 |
| 2028 | $190 |
| 2029 | $220 |
| 2030 | $246.81 |
These projections assume Rocket Lab executes on Neutron and integrates Iridium without derailing gross margin expansion. Significant upside or downside could come from Neutron’s inaugural launch outcome.
The 24/7 Wall St. price target of $120.55 reflects a buy with 50% confidence. The scale tips on backlog: a record $2.36 billion, plus $1 billion of Q3 signings, gives Rocket Lab multi-year revenue visibility that few peers can match.
The bull thesis hinges on Neutron delivering by year-end 2026 and the Iridium deal closing cleanly. The bear case rests on accelerating dilution or Neutron slipping into 2027. On balance, the risk-reward profile skews constructive.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks